Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Celldex Therapeutics provided a comprehensive update at the Morgan Stanley Global Healthcare Conference, highlighting significant progress for its lead asset, barzolvolimab. The company emphasized barzolvolimab's "unprecedented" long-term durability in Chronic Spontaneous Urticaria (CSU), where 41% of patients maintained a complete response seven months post-treatment cessation, differentiating it from existing therapies like Xolair. Celldex is advancing barzolvolimab in two global Phase III CSU studies, with further Phase II/III data readouts anticipated through 2026 across various mast cell-mediated indications, including Chronic Inducible Urticaria, Prurigo Nodularis, and Atopic Dermatitis. Additionally, updates were given on the bispecific antibody CDX-622, with initial healthy volunteer data expected by year-end, all supported by a robust cash position of $630 million, providing runway through 2027-2028 to fund these key development milestones.

Analysis

Celldex Therapeutics (CLDX) presented a robust outlook for its lead asset, barzolvolimab, a c-KIT targeting antibody, at the Morgan Stanley conference. The company highlighted unprecedented durability data from its Phase II Chronic Spontaneous Urticaria (CSU) study, where 41% of patients maintained a complete response seven months after treatment cessation, a significant potential advantage over existing therapies like Xolair, which see a rapid return of symptoms. This durability, coupled with a reversible safety profile, is being further evaluated in two global Phase III studies targeting 1,830 patients. Management confirmed these trials are enrolling as expected and include Xolair-experienced patients to support a broad label claim. The pipeline for barzolvolimab is expanding into other mast cell-mediated diseases, with 20-week placebo-controlled data for Chronic Inducible Urticaria (CIndU) expected in Q4 2025, and Phase II data for Prurigo Nodularis (PN) and Atopic Dermatitis (AD) anticipated in 2026. Financially, the company is in a strong position, holding $630 million in cash, which provides a runway through 2027-2028, sufficient to fund operations through these key clinical readouts. Beyond barzolvolimab, the bispecific antibody CDX-622 is progressing, with initial healthy volunteer data expected by year-end 2025, offering long-term pipeline depth.

Key Decisions for Investors

• Investors should recognize the significant potential of barzolvolimab's durability profile, as the 7-month post-treatment efficacy in CSU could establish a best-in-class asset if replicated in the ongoing pivotal Phase III trials.
• The stated cash runway through 2027-2028 substantially mitigates near-term financing risk, allowing the company to reach multiple key value inflection points, including Phase III CSU data and several mid-stage readouts across other indications.
• Monitor upcoming catalysts closely, particularly the 20-week placebo-controlled data from the CIndU study in Q4 2025, which will serve as a critical validation point for barzolvolimab's efficacy beyond its lead indication.
• Consider Celldex's competitive positioning; while data is strong, the definitive Phase III results will be crucial for competing against established biologics from Sanofi and potential new small molecules from Novartis in a crowded immunology market.